Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction

Biochemical Pharmacology

Volumn 68, Issue 2, 2004, Pages 395-402

  Peterson, Theresa C ^a   Peterson, Marc R ^a   Wornell, Philip A ^a   Blanchard, Matthew G ^a   Gonzalez, Frank J ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AHH; arylhydrocarbon hydroxylase; CIPRO; ciprofloxacin; CYP1A2; Cyp1A2 knockout; CYP2E1; EROD; ethoxyresorufin o deethylase; FURA; furafylline; pentoxifylline; Proliferation; PTX

Indexed keywords

CIPROFLOXACIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; FURAFYLLINE; PENTOXIFYLLINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; LIVER MICROSOME; MALE; METABOLISM; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOTTING, WESTERN; CIPROFLOXACIN; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; DRUG INTERACTIONS; ENZYME INHIBITORS; LIVER; MALE; MICE; MICE, KNOCKOUT; PENTOXIFYLLINE; PERTUSSIS TOXIN;

EID: 2942604530     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.03.035     Document Type: Article

References (40)

1. Peterson T.C. PTX prevents fibrosis in an animal model and inhibits platelet derived growth factor driven proliferation of fibroblasts. Hepatology. 17:1993;486-493
2. Thompson J., Bianco J., Benyunes M., Neubauer M., Slattery J., Fefer A. Phase 1B trial of PTX and CIPRO in patients treated with interleukin-2 and lymphokine activated killer cell therapy for metastatic renal cell carcinoma. Canc Res. 54:1994;3436-3441
3. Isbrucker R.A., Peterson T.C. Effect of PDGF, PTX and M-1 on collagen production in porcine hepatic stellate cells. Hepatology. 22:1995;4
4. Tassaneeyakul W., Birkett D. Direct characterization of the selectivity of FURA as an inhibitor of human cytochromes P-450 1A1 and 1A2. Pharmacogenetics. 4:1994;281-284
5. Pineau T., Fernandez-Saguaro P., Lee S.S., McPhail T., Ward J.M., Gonzalez F.J. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P4501A2. PNAS. 92:1995;5134-51348
6. Hodgson P.D., Peterson T.C. Effect of PTX in a heterologous serum model of fibrosis in the rat. Hepatology. 22:1995;4
7. Blanchard M.G., Peterson T.C. Increased level of antifibrotic drugs due to selective inhibition of CYP1A2. Hepatology. 30:1999;558A
8. ElDefrawy E.L., Masry S., Cohen G., Mannering G. Drug Metab Dispos. 2:1974;267
9. Bradford M. A rapid insensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254
10. Hemsworth T.C., Renton K.W. Depression of theophylline metabolism and elimination by troleandomycin and erythromycin. Biochem Pharmacol. 30:1981;1299-1301
11. Wornell P.A., Peterson T.C. Investigation of the PTX/CIPRO drug interaction in the mouse. Hepatology. 26:1997;453A
12. Fuhr U., Anders E., Mahan G., Sorgel F., Staib A. Inhibitory potency of quinolone antibacterial agents against cytochrome P-450 1A2 activity in vivo and in vitro. Antimicrob Agents Chemother. 36:1992;942-948
13. Newton D., Wang R., Lu A. Cytochrome P-450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 23:1995;154-158
14. Nebert D.W., Gelboin H.V. Substrate-inducible microsomal arylhydrocarbon hydroxylase in mammalian cell culture. J Biol Chem. 243:1968;6242-6249
15. Burke M.D., Mayer R.T. Ethoxyresorufin: direct fluorometric assay of a microsomal o-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos. 2:1974;583-588
16. Dohlman J.G., Payan D.G., Goetzl E.J. Generation of a unique fibroblast activating factor by human monocytes. Immunol. 52:1984;577-584
17. Peterson T.C., Isbrucker R. Fibroproliferation in liver disease: role of monocyte factors. Hepatology. 15:1992;191-197
18. Peterson T.C., Isbrucker R., Hooper M. In vitro effect of platelet derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacol. 28:1994;259-270
19. Peterson T.C. Inhibition of fibroproliferation by PTX activity of M-1 and lack of a role of adenosine receptors. Biochem Pharmacol. 52:1996;597-602
20. 14C after oral administration to rats dogs and humans Arzneim. Forsch. 22:1972;1933-1937
21. Hinze H. Zur pharmakokinetik von 3, 7-dimethyl-1-(5-oxo-hexyl)-zanthin (BL191) am menschen. Arzneim Forsch. 22:1972;1492-1495
22. Wills R.J., Waller E.S., Puri S.K., Ho I., Yakatan G. Influence of food on the bioavailability of Trental (PTX) in man. Drug Dev. Ind. Pharm. 7:1981;385-396
23. Luke D.R., Rocci M., Hoholick C. Inhibition of PTX clearance by cimetidine. J Pharm Sci. 75:1986;155-157
24. Smith R., Waller E., Doluisio J., Bauza M., Puri S., Ho I., et al. Pharmacokinetic of orally administered PTX in humans. J Pharm Sci. 75:1986;47-52
25. Aviado D., Dettelbach H. Pharmacology of PTX: a hemorrheologic agent for the treatment of intermittent claudication. Angiology. 35:1984;407-417
26. Ward A., Clissold S.P. PTX, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 34:1987;50-97
27. Isbrucker R.A., Peterson T.C. Platelet-derived growth factor and PTX modulation of collagen synthesis in myofibroblasts. Toxicol Appl Pharmacol. 149:1998;120-126
28. Mauro V., Mauro L., Hageman J. Comparison of PTX pharmacokinetics between non smokers and non smokers. J. Clin Pharmacol. 32:1992;1054-1058
29. Reims A., Poirier J., Lecoz F., Midavaine M., Lecocq B., Grange J., et al. Pharmacokinetics of intravenous and oral PTX in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther. 47:1990;354-359
30. Kalow W., Tang B.K. Caffeine as a metabolic probe: exploration of the enzyme inducing effect of cigarette smoking. Clin Pharmacol Ther. 49:1991;44-48
31. PA (P450 1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N oxidation of carcinogenic arylamines. PNAS. 86:1989;7696-7700
32. Loi C.M., Day J.D., Jue S.G., Bush E.D., Costello P., Dewey L.V., et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther. 45:1989;476-486
33. Rice G.C., Brown P.A., Nelson R.J., Bianco J.A., Singer J.W., Bursten S. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. PNAS. 91:1994;3857-3861
34. Garton K.J., Yuen P., Meinwald J., Thummel K.E., Kharasch E.D. Stereoselective metabolism of enflurane by human liver cytochrome P4502E1. Drug Metab Dispos. 23:1995;1426-1430
35. Pollak P.T., Slayter K.L. Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. Ann Pharmacother. 31:1997;61-64
36. Otero M.J., Moran D., Valverde M.P. Interaction between phenytoin and ciprofloxacin. Ann. Pharmacother. 33:1999;251-252
37. George J., Murray M., Byth K., Farrell G. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 21:1995;120-128
38. Peterson T.C. Monocyte aryl hydrocarbon hydroxylase activity and mortality. Clin Invest Med. 14:1991;72-76
39. Peterson T.C., Williams C.N. Depression of peripheral blood monocyte AHH activity in patients with liver disease: possible involvement of macrophage factors. Hepatology. 7:1987;333-337
40. Peterson T.C., Malatjalian D.A., Williams C.N. Monocyte arylhydrocarbon hydroxylase (AHH) activity mimics Kupffer cell and hepatocyte AHH activity in an animal model of liver disease. Can J Physiol Pharmacol. 69:1991;1797-1803